Juno Therapeutics (JUNO) Stock Price, News & Analysis

Company Overview

Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Its product candidates JCAR017, JCAR014, and JCAR015, as well as an additional early stage product candidate incorporating a fully human binding domain, leverage CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. Its CAR product candidate JCAR018 targets CD22, a different protein commonly expressed on the surface of B cell leukemias and lymphomas. Its MUC-16 directed product candidate is an armored CAR that secretes the cytokine interleukin 12 (IL-12), which may help to overcome the inhibitory effects that the tumor microenvironment can have on T cell activity.

Key Stats

• Today's Range: $86.96 to $86.96
• 50-Day Range: $86.96 to $86.96
• 52-Week Range: $19.62 to $87.01
• Volume: 2 shs
• Average Volume: 5.48 million shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

JUNO Stock Analysis - Frequently Asked Questions

How were Juno Therapeutics' earnings last quarter?

Juno Therapeutics Inc (NASDAQ:JUNO) released its quarterly earnings data on Wednesday, November, 1st. The biopharmaceutical company reported ($0.73) EPS for the quarter, topping analysts' consensus estimates of ($0.80) by $0.07. The firm's quarterly revenue was up 115.4% on a year-over-year basis.

When did Juno Therapeutics IPO?

Juno Therapeutics (JUNO) raised $153 million in an IPO on Friday, December 19th 2014. The company issued 9,300,000 shares at a price of $15.00-$18.00 per share. Morgan Stanley, J.P. Morgan and Goldman Sachs served as the underwriters for the IPO and Leerink Partners was co-manager.

What other stocks do shareholders of Juno Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Juno Therapeutics investors own include Bristol Myers Squibb (BMY), (KITE) (KITE), bluebird bio (BLUE), Gilead Sciences (GILD), Meta Platforms (META), Puma Biotechnology (PBYI) and BioMarin Pharmaceutical (BMRN).

Company Calendar

• Last Earnings: 11/01/2017
• Today: 10/16/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:JUNO
• CIK: 1594864
• Web: www.junotherapeutics.com
• Phone: +1-206-5821600
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Optionable
• Beta: N/A